Literature DB >> 1637731

Enalapril versus combined enalapril and nadolol treatment: effects on blood pressure, heart rate, humoral variables, and plasma potassium at rest and during exercise in hypertensive patients.

P A Sullivan1, B Daly, R O'Connor.   

Abstract

The effect of enalapril alone and in combination with nadolol on resting and exercising blood pressure, heart rate, plasma renin activity, aldosterone, noradrenaline, and potassium levels was studied in 10 hypertensive patients (diastolic blood pressure between 95 and 114 mmHg). Patients received placebo for 4 weeks, enalapril (mean daily dose 24.5 mg) for 8 weeks, and nadolol, 40 mg once daily, was added for the remaining 8 weeks of the study. Exercise testing (modified Bruce, treadmill) was conducted at the end of the placebo run-in phase and at the end of each treatment period. Enalapril reduced resting and exercising blood pressure independent of any change in heart rate: This effect was increased with combination treatment. Plasma renin activity at rest and during exercise was increased by enalapril. Combination treatment attenuated this response and significantly reduced plasma aldosterone. Neither treatment had any effect on plasma noradrenaline levels. Resting plasma potassium levels were increased with combination treatment, whereas both treatment regimens increased plasma potassium levels during exercise. There were no clinically relevant episodes of hyperkalemia. Further investigation is required to qualify the nature of the blood pressure and plasma potassium response with combination treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1637731     DOI: 10.1007/bf00051148

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  22 in total

1.  Hypertension, exercise, and beta-adrenergic blockade.

Authors:  P A Ades; P G Gunther; C P Meacham; M A Handy; M M LeWinter
Journal:  Ann Intern Med       Date:  1988-10-15       Impact factor: 25.391

Review 2.  Clinical pharmacology of ACE inhibition.

Authors:  J Nussberger; B Waeber; H R Brunner
Journal:  Cardiology       Date:  1989       Impact factor: 1.869

3.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

4.  Arterial plasma potassium measured continuously during exercise in man.

Authors:  R A Linton; M Lim; C B Wolff; P Wilmshurst; D M Band
Journal:  Clin Sci (Lond)       Date:  1984-10       Impact factor: 6.124

5.  Hemodynamic response to captopril at rest and during exercise in hypertensive patients.

Authors:  R Fagard; P Lijnen; A Amery
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

6.  Captopril attenuates pressor responses to norepinephrine and vasopressin through depletion of endogenous angiotensin II.

Authors:  Y Imai; K Abe; M Seino; T Haruyama; J Tajima; K Yoshinaga; H Sekino
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

7.  Role of sympathetic nervous system activity in the blood pressure response to long-term captopril therapy in severely hypertensive patients.

Authors:  M H Weinberger
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

8.  Comparison of antihypertensive and hormonal effects of captopril and propranolol at rest and during exercise.

Authors:  T G Pickering; D B Case; P A Sullivan; J H Laragh
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

9.  Central and peripheral indices of sympathetic activity after blood pressure lowering with enalapril (MK-421) or hydralazine in normotensive rats.

Authors:  O Kohlmann; M Bresnahan; H Gavras
Journal:  Hypertension       Date:  1984 Mar-Apr       Impact factor: 10.190

10.  Differentiation of hemodynamic, humoral and metabolic responses to beta 1- and beta 2-adrenergic stimulation in man using atenolol and propranolol.

Authors:  A A McLeod; J E Brown; C Kuhn; B B Kitchell; F A Sedor; R S Williams; D G Shand
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.